ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Hepatitis C"

  • Abstract Number: 948 • 2019 ACR/ARP Annual Meeting

    Relapsing Cryoglobulinemic Vasculitis Following Successful HCV Eradication by Interferon-Free Direct Acting Antivirals, an International Multicenter Study

    Mohamed Tharwat Hegazy1, Ahmed Fayed 1, Tarek El Shabony 1, Marcella Visentini 2, David Saadoun 3, Patrice Cacoub 3 and Gaafar Ragab 1, 1Cairo University, Cairo, Egypt, Cairo, Egypt, 2Sapienza University of Rome, Rome, Italy, Rome, Italy, 3AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France

    Background/Purpose: Interferon-free Direct Acting Antiviral (DAA) combinations proved to be effective for the treatment of HCV induced Cryoglobulinemic Vasculitis (HCV-Cryovas). Some reports showed relapses of…
  • Abstract Number: 2101 • 2019 ACR/ARP Annual Meeting

    Hepatitis C Affects More Than Just the Liver: A Retrospective Chart Review on the Prevalence of Connective Tissue Diseases and Autoantibodies in Hepatitis C Virus Infections in an Academic Rheumatology Clinic

    Matthew Malus1, Ly-Elaine Pham 1, Hrishikesh Samant 1 and Mamatha Katikaneni 2, 1Louisiana State University Health Sciences Center in Shreveport, Shreveport, LA, 2LSUHSC- Shreveport, Shreveport, LA

    Background/Purpose: Chronic Hepatitis C virus infection (HCV) has been shown to be associated with connective tissue diseases (CTD). It has been hypothesized that HCV can…
  • Abstract Number: 831 • 2018 ACR/ARHP Annual Meeting

    No More HCV RNA in Serum and Cryoprecipitate in Patients with Persisting HCV-Cryoglobulinemia Vasculitis after Daa-Induced Sustained Virological Response

    Patrice Cacoub1, Eve Todesco2, Pascale Ghillani-Dalbin3, Lucile Musset3 and David Saadoun4, 1Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, Paris, France, 2Virology Pitie Salpetriere hospital, Paris, France, 3Immunobiology department Pitie Salpetriere Hospital, Paris, France, 4Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France

    No more HCV RNA in Serum and Cryoprecipitate in Patients with Persisting HCV-Cryoglobulinemia Vasculitis after DAA-induced Sustained Virological ResponseBackground/Purpose: In addition to high antiviral efficacy,…
  • Abstract Number: 1479 • 2018 ACR/ARHP Annual Meeting

    The Predictive Utility of Anti-Cyclic Citrullinated Peptide Antibodies to Diagnose Rheumatoid Arthritis in Patients with Hepatitis C and Polyarthralgias

    Divya Jayakumar1,2, Xinliang Huang1,2, Seth Eisen1,2, Prabha Ranganathan1,2 and Amy Joseph2,3, 1Rheumatology, VA St. Louis Health Care System, St Louis, MO, 2Rheumatology, Washington University School of Medicine, St Louis, MO, 3Rheumatology, VA St. Louis Health Care System, St. Louis, MO

    Background/Purpose: Joint pain is a common extra-hepatic manifestation of chronic hepatitis C (HCV) infection. HCV infection is often associated with the presence of autoantibodies such…
  • Abstract Number: 829 • 2018 ACR/ARHP Annual Meeting

    DNA Damage and Repair in Patients with Cryoglobulinemic Vasculitis Treated with Direct Anti-HCV Drugs

    Mohamed Tharwat Hegazy1, Walaa Allam2, Mohamed A Hussein1, Naguib Zoheir3, Luca Quartuccio4, Patrice Cacoub5, Wahid Doss6, Mona I. Ellawindi7, Mary Fawzy1, Loïc Guillevin8, Ahmed El Ray9, Maissa El Said El Raziky10,11, Magdy El Serafy6, Sherif El Khamisy2,12 and Gaafar Ragab1, 1Internal Medicine Department, Rheumatology and Clinical Immunology Unit, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, 2Center for Genomics, Zewail City of Science and Technology, Giza, Egypt, Giza, Egypt, 3Clinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, 4Rheumatology Clinic, Academic Hospital S. M. della Misericordia, Medical Area Department, University of Udine, Italy, Udine, Italy, 5Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, Paris, France, 6Tropical Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, 7Community Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, 8Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, 9Theodor Bilharz Research Institute, Cairo, Egypt, Cairo, Egypt, 10Fatimid Cairo hospital, Cairo, Egypt, Cairo, Egypt, 11Tropical Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, cairo, Egypt, 12Krebs Institute, University of Sheffield, Sheffield, S10 2TN, UK, Sheffield, United Kingdom

    DNA Damage and Repair in Patients with Cryoglobulinemic Vasculitis Treated with Direct Anti-HCV Drugs Background/Purpose: Direct Acting Antiviral (DAA) agents were shown to be effective…
  • Abstract Number: 281 • 2017 ACR/ARHP Annual Meeting

    Direct Medical Costs Associated with the Extrahepatic Manifestations of Hepatitis C Virus Infection in France

    Patrice Cacoub1, Mathieu vautier2, Anne-Claire Desbois3, David Saadoun4 and Zobair Younossi5, 1Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, 2Médecine Interne 1, Hôpital Pitié-Salpêtrière, Paris, France, 3Hôpital Pitié-Salpêtrière, Internal Medicine and Clinical Immunology, Paris, France, 4Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France, 5Medicine, Inova Fairfax Hospital, Falls Church, Falls Church, VT

    Background/Purpose: The economic impact of the extrahepatic manifestations (EHM) of hepatitis C virus (HCV) infection remains unknown for France. To estimate the prevalence of HCV-EHM…
  • Abstract Number: 894 • 2017 ACR/ARHP Annual Meeting

    All Oral Interferon-Free Antivirals for Hepatitis C Virus Cryoglobulinemia Vasculitis: A Long Term Follow up Multicenter International Study

    Patrice Cacoub1, Si Nafa Si Ahmed2, Yasmina FerFar3, SN Pol4, Dominique Thabut5, Christophe Hezode6, Laurent Albric7, Cloé Comarmond8,9,10, Gafaar Ragab11, Luca Quartuccio12, Mohamed Hegazy13, Thierry Poynard5, Mathieu Resche-Rigon14 and David Saadoun15, 1Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, 2Hôpital Orléans, Orléans, France, 3Internal Medicine, Hopital Pitié-Salpetrière, Paris, France, 4Department of Hepatology, APHP, Hôpital Cochin, Paris, paris, France, 5Groupe Hospitalier Pitié-Salpétrière, Paris, France, 6Hôpital Henri Mondor, Creteil, France, 7Centre hospitalier universitaire Purpan, Purpan, France, 8Internal Medicine and Clinical Imunology, Referal Center for Autoimmune diseases, Internal Medicine and Clinical Imunology, Hôpital Pitié Salpétrière, Paris, France, 9DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, 10Internal Medicine, Hôpital Pitié Salpétrière, Paris, France, 11Cairo University, Cairo, Egypt, 12University Hospital "Santa Maria della Misericordia, Udine, Italy, 13Faculty of Medicine – Cairo University, Cairo, El Salvador, 14Hôpital Saint-Louis, Paris, France, 15Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France

    Background/Purpose: Interferon (IFN) containing regimens used for hepatitis C virus (HCV)-cryoglobulinemia vasculitis (CryoVas) are poorly effective and associated with important side effects. In small-size and…
  • Abstract Number: 1355 • 2017 ACR/ARHP Annual Meeting

    14-3-3η:  Useful for More Than the Diagnosis of Rheumatoid Arthritis?

    Lisa Zickuhr1, Maryam Pourpaki2, Martha M. Brooks3 and Amy Joseph4, 1Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, 2Rheumatology, Advocate Christ Medical Center at Chicago, Oak Lawn, IL, 3Rheumatology, St. Louis VA Medical Center, St. Louis, MO, 4Rheumatology, Veterans Administration Central Office, St. Louis, MO

    Background/Purpose: Chronic hepatitis C virus (HCV) infection can masquerade as rheumatoid arthritis (RA). Distinguishing between the two is important because treatments differ. 14-3-3η has been…
  • Abstract Number: 2221 • 2017 ACR/ARHP Annual Meeting

    Eradication of Hepatitis C Among US Veterans: Examination of Changes in Pain Severity and Prescription Opioid Use Following Treatment

    Anand Kumthekar1, Sarah Shull2, Benjamin Morasco3,4, Travis Lovejoy3,4, Michael Chang2 and Jennifer Barton3, 1Rheumatology, Oregon Health & Science University, Portland, OR, 2Gastroenterology, VA Portland Health Care System, Portland, OR, 3VA Portland Health Care System, Portland, OR, 4Oregon Health & Science University, Portland, OR

    Background/Purpose: Hepatitis C virus (HCV) is associated with chronic wide spread pain, fatigue, myalgia, arthritis, sicca symptoms and vasculitis. Data regarding prior interferon-based treatment of…
  • Abstract Number: 2741 • 2017 ACR/ARHP Annual Meeting

    Rheumatoid Factor (RF) Levels Remain Persistently Elevated 24 Weeks after Interferon (INF) Free Direct Antiviral Agents (DAA) Therapy in the Majority of RF+ HCV Infected Persons

    Corinne Kowal1, Carey Shive2,3, Elizabeth Zebrowski4,5, Lenche Kostadinova1,6, Brianna Fuller1,6, Elane Reyes2, Kelsey Rife4, Amy Hirsch4, Anita Compan4, Shyam Kottilil7, Yngve Falck-Ytter6,8, Leonard H. Calabrese9, Donald Anthony4,6,10,11 and Maya Mattar6,12, 1Department of Medicine, Louis Stokes VA Medical Center, Cleveland, OH, 2Department of Medicine and Pathology, Case Western Reserve University, Cleveland, OH, 3VA Geriartic Research and Education Clinical Center (GRECC), Louis Stokes VA Medical Center, Cleveland, OH, 4Louis Stokes VA Medical Center, Cleveland, OH, 5Department of Medicine, Case Western Reserve University, Cleveland, OH, 6Case Western Reserve University, Cleveland, OH, 7IHV Clinical Research Unit, University of Maryland, Baltimore,, Baltimore, MD, 8Internal Medicine/ Division of gastroenterology, Louis Stokes VA Medical Center, Cleveland, OH, 9Rheumatic & Immunologic Disease and Infectious Disease, Cleveland Clinic Foundation, Cleveland, OH, 10Division of Medicine and Pathology, Divisions of Infectious and Rheumatic diseases, University Hospitals Cleveland Medical Center, Cleveland, OH, 11VA Geriatric Research and Education Clinical Center (GRECC), Cleveland, OH, 12Internal Medicine/ Division of Rheumatology, University Hospitals Cleveland Medical Center, Cleveland, OH

    Background/Purpose: Cryoglobulinemic vasculitis (CV) is an extrahepatic manifestation of chronic HCV infection. It varies in severity from mild to life threatening. Some but not all…
  • Abstract Number: 17L • 2016 ACR/ARHP Annual Meeting

    Sofosbuvir Plus Daclatasvir for Hepatitis C Virus Associated Cryoglobulinemia Vasculitis

    David Saadoun1, yasmina ferfar1, AS Bouyer2, laurent alric3, christophe hezode4, SN Si Ahmed5, L Musset6, Luc De Saint Martin Pernot7, SN Pol8, Dominique Larrey9, T Poynard10 and Patrice Cacoub2, 1Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France, 2Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, paris, France, 3Department of Internal Medicine-Digestive, Centre hospitalier universitaire Purpan, UMR 152 Toulouse 3 University, Toulouse, toulouse, France, 4Department of Hepatology, APHP, Hôpital Henri Mondor, Créteil, creteil, France, 5Department of Hepatology, Hôpital Orléans, Orléans, Orleans, France, 6Department of Immunology, UF d’Immunochimie et d’autoimmunité, APHP, Groupe Hospitalier Pitié-Salpétrière, Paris, France, paris, France, 7Department of internal medicine, CHRU Brest, Brest, France, 8Department of Hepatology, APHP, Hôpital Cochin, Paris, paris, France, 9Department of hepatology, CHRU Montpellier, France, montpellier, France, 10Department of Hepatology, APHP, Groupe Hospitalier Pitié-Salpétrière, Paris, paris, France

    Background/Purpose: Hepatitis C virus (HCV) is the aetiological agent for most cases of cryoglobulinemia vasculitis. Interferon containing regimens are associated with important side effects and…
  • Abstract Number: 1322 • 2016 ACR/ARHP Annual Meeting

    Use of Biologics in Arthritis Patients with Hepatitis B and C ‏: A Multicentral Retrospective Case Series

    Sultana Abdulaziz1, Hessein Halabi2, Mohammed Omair3, Suzan Attar4, Mohammed Shabrawishi5, Abdulwahab Neyazi6, Haneen Alnazzawi7, Noha Meraiani8 and Hani Almoallim9, 1Dept of Medicine/Unit of Rheumatology, King Fahad Hospital, Jeddah, Saudi Arabia, 2Department of Medicine, King Faisal Specialist Hospital,, Jeddah, Saudi Arabia, 3Dept of Medicine, Div of Rheumatology, King Saud University, Riyadh, Saudi Arabia, 4Internal Medicine, FRCPC, ABIM, Professor in Medicine, Jeddah, Saudi Arabia, 5Department of Medicine, King Faisal Specialist Hospital, Jeddah, Saudi Arabia, 6Department of Medicine, King Abdullah Medical City, Jeddah, Saudi Arabia, 7King Faisal Specialist Hospital, JEDDAH, Saudi Arabia, 8Department of Medicine, National Guard Hospital, JEDDAH, Saudi Arabia, 9Department of Medicine, Umm Alqura University, Makkah, Saudi Arabia, Makkah, Saudi Arabia

    Use of biologics in arthritis patients with Hepatitis B and C ‏: a multicentral retrospective case series   Abstract Background/Purpose: Reactivation of viral hepatitis B…
  • Abstract Number: 2977 • 2016 ACR/ARHP Annual Meeting

    Treatment of Cryoglobulinemic Vasculitis with Sofosbuvir in Four Combination Protocols

    Mohamed Tharwat Hegazy1, Mohamed A Hussein1, Luca Quartuccio2, Mary Fawzy1, Naguib Zoheir3, Mona I. Ellawindi4, Milena Bond2, Cesare Mazzaro5, Ahmed El Ray6, Maissa El Said El Raziky7,8, Magdy El Serafy9, Wahid Doss9, Patrice Cacoub10, Loïc Guillevin11, Salvatore De Vita2, Sherif El Khamisy12 and Gaafar Ragab1, 1Internal Medicine, Internal Medicine Department, Rheumatology and Clinical Immunology Unit, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, 2Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, Udine, Italy, 3Clinical and Chemical Pathology Department, Clinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, 4Community Medicine, Community Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, 5Internal Medicine, Pordenone Hospital, Italy, pordenone, Italy, 6Theodor Bilharz Research Institute, Cairo, Egypt, Cairo, Egypt, 7Fatimid Cairo hospital, Cairo, Egypt, Cairo, Egypt, 8Tropical Medicine, Tropical Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, cairo, Egypt, 9Tropical Medicine, Tropical Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, 10Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, 11Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, 12Zewail city of Science and Technology, Egypt, Giza, Egypt

    Background/Purpose: Cryoglobulinemic Vasculitis (CV) is a systemic vasculitis affecting small and medium-sized vessels. Following emergence of direct acting antiviral drugs, which paved the way to…
  • Abstract Number: 1356 • 2015 ACR/ARHP Annual Meeting

    Autoimmune Manifestations in Hepatitis C: A Single-Centered Experience

    Azza Ali1, Reshma Khan1, Kirthi Lilley2, Paul Naylor2, Rajaie Namas1 and Malini Venkatram1, 1Rheumatology, Wayne State University, Detroit, MI, 2Gastroenterology, Wayne State University, Detroit, MI

    Background/Purpose: Hepatitis C infection (HCV) is a leading cause of chronic liver disease. It is associated with a plethora of autoimmune manifestations including clinical, serological…
  • Abstract Number: 1840 • 2015 ACR/ARHP Annual Meeting

    How Good a Job Are We Rheumatologists Doing in Screening for Hepatitis B and C before Immuno-Suppressive/s Initiation in SLE?

    Chandrahasa Annem1, Joel A. Block2 and Meenakshi Jolly3, 1RHEUMATOLOGY, RUSH UNIVERSITY, CHICAGO, IL, 2Rush University Medical Center, Chicago, IL, 3Department of Medicine, Section of Rheumatology, Rush University Medical Center, Chicago, IL

    Background/Purpose: Hepatitis B & C viral infections are widely prevalent and the potential of immunosuppressive medications (ISM) to exacerbate an underlying viral infection is well…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology